Ibrutinib Cessation Following Prolonged Exposure Supports Intermittent Investigation in CLL
Stable peripheral disease levels lasting 12 months were reported in patients with treatment-naïve chronic lymphocytic leukemia following 6 years of continuous treatment with ibrutinib.
United Kingdom Andyc Rawstron United Kingdom National Health Service International Workshop Hematological Malignancy Diagnostic Service Leeds Cancer Centre
Source: onclive.com